The use of volunteer, unrelated donors has substantially increased the number of potential donors for pediatric marrow transplantation during the past few years. We describe our single institution experience of short-term toxicity after pediatric marrow transplantation using sibling or unrelated donors. Fully matched (A, B and DR loci) donors were employed in 94% of the cases in both groups. Conditioning of similar intensity and uniform supportive care were employed in the two groups. Both primary non-engraftment and secondary graft failure were more common among recipients of unmanipulated URD grafts. Clinically significant (grades III-IV) acute GVHD and toxic mortality during the immediate post-transplant period were also higher in this group of patients. Pediatric marrow transplantation using volunteer, unrelated donors appears to be associated with an increased incidence of procedure-related toxic complications.
An HLA-identical sibling exists in only about one-third of the cases where allogeneic bone marrow is needed. This has prompted the rapidly expanding, yet still experimental, use of alternative donors. During the past few years several reports of pediatric marrow transplantation using volunteer, unrelated donors (URDs) have been published. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] It appears that unrelated donors constitute a viable optional source for stem cells to be used for marrow reconstitution following myeloablative therapy in the pediatric setting. 2, 3, 6, 9 When unmanipulated URD grafts are used, the incidence of both acute and chronic GVHD, the risk of overall treatment-related toxicity and that of graft rejection appear higher 3, 6, 10 than that encountered with HLA-identical sibling donors. 6, 11 However, studies evaluating the treatment-related toxicity and concurrently comparing transplant using unrelated vs matched sibling donors and unmanipulated grafts are Correspondence: Dr K Vettenranta, Bone Marrow Transplantation Unit, Bristol Royal Hospital for Sick Children, St Michael's Hill, Bristol BS2 8BJ, UK Received 2 July 1998; accepted 26 September 1998 few 6 and involve substantially more strenuous conditioning for the recipients of URD grafts.
In this study we assessed the short-term (within 100 days post-transplant) treatment-related toxicity associated with pediatric marrow transplantation using matched sibling vs unrelated donors, with conditioning of comparable intensity and uniform supportive care measures in a single institution setting.
Patients and methods
The patients were all transplanted with non-T cell-depleted grafts in the Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Finland between September 1992 and January 1998. Key demographic data and diagnoses are given in Table 1 . There were a total of 67 patients, 50 with malignant disease and 17 with nonmalignant disease.
Donors
The sibling donors were all HLA-identical with their respective recipients except for one case with a single anti- Table 1 The patients' key demographic data and diagnoses URDs were all obtained through the Bone Marrow Registry of the Finnish Red Cross Blood Transfusion Service in Helsinki, Finland. Both domestic (n = 25) and foreign (n = 9) URDs were included. The two patients with a 5/6-match both had a single antigen mismatch at the A locus. In the Finnish setting a suitable URD can be found in about 90% of the pediatric cases.
HLA compatibility was assessed in the Tissue Typing Laboratory of the Finnish Red Cross Blood Transfusion Service by conventional serological typing for class I and II antigens. High-resolution DNA typing with sequencespecific oligonucleotide probes for class II loci was performed on patients and donors in the unrelated donor group.
All donor-recipient pairs were also evaluated using MLC. The mean reactivity in the direction of GVHD was 7% (range 0-28%) in the URD group and 1% (range 0-13%) in the sibling donor group and that in the direction of rejection 13% (range 0-64%) and 4% (range 0-16%) respectively.
CMV status
Of the donors, 39% were CMV positive in the URD group and 31% in the sibling donor group. Of the recipients, 65% and 44% were positive, respectively. In only 10% and 6% of the cases was a CMV-positive graft given to a CMVnegative donor in the two groups, respectively.
Conditioning regimen
Apart from the fact that conditioning in 11% of the recipients in the URD group involved ALG (none in the sibling donor group) and that in 97% either TBI or TLI (82% in the sibling group) was used the pretreatment was of comparable intensity in the two groups ( Table 2) .
The mean dose of TBI administered was 10 Gy (range 8-14 Gy) in the URD group and 11 Gy (range 10-12 Gy) Table 2 The key parameters related to the graft and conditioning /dose q 12 h, a total of 12 doses (Ara-C); cyclophosphamide either 50 mg/kg/day for 4 days, 60 mg/kg/day for 2 days or 40 mg/kg/day for 3 days (Cy), all with Mesna; busulfan 4 mg/kg/day q 6 h for 4 days with cyclophosphamide 50 mg/kg/day for 4 days with Mesna (BuCy); melphalan 140 mg/m 2 single dose on day 1 and 70 mg/m 2 on day 2 (L-PAM); anti-lymphocyte globulin (Lymphoglobuline; Pasteur-Merieux, Lyon, France) 30 mg/kg/day for 3 or 5 days (ALG). Three patients also received etoposide; one patient received ifosfamide and another doxorubicin.
Donor group
URD (n = 34) Sibling (n = 33)
Engraftment
Patients exceeding an ANC level of 500 ϫ 10 6 /l were considered engrafted. Non-engraftment was defined as the absence of signs of hematopoiesis at day 28 post-transplant or later, or with autologous marrow reconstitution.
Supportive care
All patients were housed in two-door isolation while neutropenic with an ANC р300 ϫ 10 6 /l. The policies for fungal and Pneumocystis (co-trimoxazole) prophylaxis were identical in the two groups. No anti-bacterial or -viral prophylaxis was employed. All blood products were irradiated and filtered. Policies in choosing the primary drug combination for anti-bacterial treatment, focusing or altering the combination when needed and initiating systemic antifungal or antiviral medication were identical in the two groups. Hematopoietic growth factors were administered and parenteral nutrition was given following common guidelines.
GVHD
All patients survived beyond day ϩ28 post-transplant and were considered at risk for GVHD. The regimen for GVHD prophylaxis using cyclosporin A from day Ϫ1 on and methotrexate i.v. on days ϩ1, ϩ3, ϩ6 and ϩ11 was identical in the two groups as were the criteria for initiating treatment for established GVHD. Clinical acute GVHD was graded according to conventional criteria. 12 
Statistical evaluation
In statistical analysis the 2 test and StatView 4.5 sofware were employed.
Results
Risk for primary non-engraftment and for early (prior to 100 days post-transplant) secondary graft failure was significantly (P Ͻ 0.05) higher in the URD group. Particularly, those with a foreign donor tended to be at higher risk (3/8 vs 3/24 in the foreign and domestic donor groups, respectively). In contrast, speed of engraftment among those engrafting was the same in the URD and sibling donor groups. Eighty-five percent of patients in the URD group and 73% of those in the sibling donor group had fever of unknown origin at some point during their post-transplant course. Culture-positive bacterial infections also occurred at a similar rate in the two groups. In contrast, documented infections (mostly viremia) caused by CMV seemed more prevalent in the URD group. Occasional patients in both groups also suffered infections caused by other viruses (RSV, HSV, adenovirus) ( Table 3) .
The risk for clinically significant (grades III-IV) acute GVHD inclined to be higher among the engrafted recipients of URD grafts (26% vs 9% in the URD and sibling groups, Table 3 The key parameters related to the post-transplant course None  7  15  Grades 1-II  18  15  Grades III-IV  9  3  Skin only 10/27 10/17 ϩGI tract 9/27 6/17 ϩGI tract ϩ liver 6/27 1/17 Died (Ͻ100 day post-transplant) 6 3 respectively). In contrast, the likelihood of not developing clinical signs of GVHD at all was significantly higher among those transplanted from sibling donors (21% vs 45% (in the URD and sibling groups, respectively (P Ͻ 0.05) (Figure 1 ). Acute GVHD encompassing skin, GI tract and liver also appeared more common among those transplanted with a URD graft (Table 3) . Toxicity in the form of hepatic veno-occlusive disease and/or clinically significant thrombotic microangiopathy was encountered in only occasional patients in both groups.
Toxic mortality during the early (prior to 100 days) posttransplant period also appeared to be higher among those transplanted using unrelated donors (18% vs 7% in the URD and sibling groups respectively). In the URD group cause of death was bleeding in two, infection complicated by multi-organ failure and GVHD in two and infection, multi-organ failure, thrombotic microangiopathy and GVHD in two cases. In the sibling donor group the cause of death was ALL relapse in one, infection in one and infection, multi-organ failure, thrombotic microangiopathy and putative GVHD in one case.
Discussion
Bone marrow transplantation using unrelated vs sibling donors appears to be associated with a higher incidence of procedure-related complications. 6, 13 Overall treatmentrelated mortality has been reported to exceed 50% 13 while that among pediatric recipients of URD grafts appears somewhat lower. 3, 6 Toxic mortality within the first 100 days post-transplant among recipients of URD grafts appears to be in the order of 15-35% 3, 6, 8, 10 and among recipients of sibling grafts in the order of 10-15%. 14 Eighteen percent recent of our recipients of URD grafts and 7% of those with a sibling donor died of treatment-related causes during the first 100 days, post-transplant.
The key factors influencing treatment-related morbidity and mortality following marrow transplantation from an unrelated donor include infection and/or GVHD, hemorrhage and non-engraftment. Compared to those receiving unmanipulated grafts. 1, 6 the relative contribution of each is substantially altered by T cell depletion of the graft. 2, 9 The incidence of clinically significant acute GVHD (grades III-IV) among recipients of unmanipulated marrow grafts from unrelated donors has been reported to be in the range of 23% to 37%, 6, 8, 10 with that among our patients being 26%.
As to the likelihood of non-engraftment among the recipients of URD grafts, our experience (18%) is slightly higher than that reported by others (2-11% 2, 3, 5, 6, 8, 10 ) while that of secondary graft failure 6 is comparable to that reported previously. 8, 10 Furthermore, among recipients of URD grafts the possibly slightly reduced risk of a relapse is markedly offset by a significantly higher incidence of chronic GVHD when compared to that of sibling grafts. 13 As a consequence, in the great majority of institutions the seemingly higher incidence of procedure-related complications involved in marrow transplantation using URD grafts also translates into substantially increased costs.
Within our group of sibling marrow recipients the parameters discussed above are comparable to those recently reported by other centers 6, 11 and compare favorably (eg probability of engraftment, the risk for severe acute GVHD, non-relapse mortality) with those of the earlier years of marrow transplantation reported from our unit. 14 Our experience indicates that even when recipients of HLA-identical sibling or unrelated donor marrow grafts are subjected to pre-transplant conditioning of essentially the same intensity with the principles of supportive care being identical, the latter encounter more procedure-related complications of a toxic nature. Primary non-engraftment, early secondary graft failure, infectious complications, severe acute GVHD and short-term, non-relapse mortality appear higher among the recipients of URD grafts. Therefore, despite the seemingly somewhat better graft-versus-leukemia effect ofter URD grafts, 13 our current thinking on the indications for marrow transplantation using unrelated donors remains influenced by the above. 15 In conclusion, pediatric marrow transplantation with unmanipulated grafts from volunteer, unrelated donors seems to involve substantial procedure-related toxicity when compared to that employing grafts from HLA-identical sibling donors. Therefore, novel approaches which do not increase the risk of non-engraftment/graft failure or relapse but which enhance graft compatibility with host tissues and function of the unrelated donor graft (eg selective graft manipulation) are needed.
